These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16967346)

  • 1. Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker.
    Jadhav PR; Agersø H; Tornøe CW; Gobburu JV
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):609-34. PubMed ID: 16967346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues.
    Tornøe CW; Agersø H; Senderovitz T; Nielsen HA; Madsen H; Karlsson MO; Jonsson EN
    Br J Clin Pharmacol; 2007 Jun; 63(6):648-64. PubMed ID: 17096678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
    Broqua P; Riviere PJ; Conn PM; Rivier JE; Aubert ML; Junien JL
    J Pharmacol Exp Ther; 2002 Apr; 301(1):95-102. PubMed ID: 11907162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers.
    Pechstein B; Nagaraja NV; Hermann R; Romeis P; Locher M; Derendorf H
    J Clin Pharmacol; 2000 Mar; 40(3):266-74. PubMed ID: 10709155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix.
    Tornøe CW; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    Pharm Res; 2004 Apr; 21(4):574-84. PubMed ID: 15139513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GnRH Antagonist Degarelix Suppresses Gonadotropin Secretion and Pituitary Sensitivity in Midgestation Sheep Fetuses.
    Amodei R; Jonker SS; Whitler W; Estill CT; Roselli CE
    Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34958103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary luteinizing hormone responses to intravenous and subcutaneous administration of gonadotropin-releasing hormone in men.
    Spratt DI; Crowley WF; Butler JP; Hoffman AR; Conn PM; Badger TM
    J Clin Endocrinol Metab; 1985 Nov; 61(5):890-5. PubMed ID: 3900124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide.
    Fattinger KE; Verotta D; Porchet HC; Munafo A; Le Cotonnec JY; Sheiner LB
    Am J Physiol; 1996 Oct; 271(4 Pt 1):E775-87. PubMed ID: 8897868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME.
    Tornøe CW; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Dec; 31(6):441-61. PubMed ID: 16222784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs.
    Agersø H; Koechling W; Knutsson M; Hjortkjaer R; Karlsson MO
    Eur J Pharm Sci; 2003 Nov; 20(3):335-40. PubMed ID: 14592699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study.
    Erb K; Pechstein B; Schueler A; Engel J; Hermann R
    Clin Pharmacol Ther; 2000 Jun; 67(6):660-9. PubMed ID: 10872648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.
    Wong SL; Lau DT; Baughman SA; Fotheringham N; Menchaca D; Garnick MB
    J Clin Pharmacol; 2004 May; 44(5):495-502. PubMed ID: 15102870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men.
    Finkelstein JS; Whitcomb RW; O'Dea LS; Longcope C; Schoenfeld DA; Crowley WF
    J Clin Endocrinol Metab; 1991 Sep; 73(3):609-20. PubMed ID: 1908484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women.
    Nagaraja NV; Pechstein B; Erb K; Klipping C; Hermann R; Niebch G; Derendorf H
    Clin Pharmacol Ther; 2000 Dec; 68(6):617-25. PubMed ID: 11180022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.
    Samant MP; Gulyas J; Hong DJ; Croston G; Rivier C; Rivier J
    J Med Chem; 2005 Jul; 48(15):4851-60. PubMed ID: 16033265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulsatile intravenous infusion of recombinant human luteinizing hormone under acute gonadotropin-releasing hormone receptor blockade reconstitutes testosterone secretion in young men.
    Veldhuis JD; Iranmanesh A
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4474-9. PubMed ID: 15356050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of pituitary gonadotropin-releasing hormone receptors by pulsatile gonadotropin-releasing hormone injections in male rats. Modulation by testosterone.
    Garcia A; Schiff M; Marshall JC
    J Clin Invest; 1984 Sep; 74(3):920-8. PubMed ID: 6088587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive effect of simultaneous continuous administration of degarelix and TAK-448 on LH suppression in a castrated rat model.
    Stalewski J; Hargrove DM; Wolfe M; Kohout TA; Kamal A
    Eur J Pharmacol; 2018 Apr; 824():24-29. PubMed ID: 29378196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.